Abstract
Substantial leaps have been made in the drug discovery front in tackling the growing pandemic of obesity and its metabolic co-morbidities. Greater mechanistic insight and understanding of the gut-brain molecular pathways at play have enabled the pursuit of novel therapeutic agents that possess increasingly efficacious weight-lowering potential whilst remaining safe and tolerable for clinical use. In the wake of glucagon-like peptide 1 (GLP-1) based therapy, we look at recent advances in gut hormone biology that have fermented the development of next generation pharmacotherapy in diabesity that harness synergistic potential. In this paper, we review the latest data from the SURPASS and SURMOUNT clinical trials for the novel 'twincretin', known as Tirzepatide, which has demonstrated sizeable body weight reduction as well as glycaemic efficacy. We also provide an overview of amylin-based combination strategies and other emerging therapies in the pipeline that are similarly providing great promise for the future of chronic management of obesity.
Original language | English |
---|---|
Pages (from-to) | 1019-1030 |
Number of pages | 12 |
Journal | Internal and Emergency Medicine |
Volume | 18 |
Issue number | 4 |
Early online date | 30 May 2023 |
DOIs | |
Publication status | Published online - 30 May 2023 |
Bibliographical note
Publisher Copyright:© 2023, Crown.
Data Access Statement
Not Applicable.Keywords
- Amylin
- Tirzepatide
- Obesity
- Glucagon-like peptide 1
- Type 2 diabetes
- Glucagon dependent insulinotropic polypeptide